13 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367 Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Where Are Biotech ETFs Headed After Q4 Earnings? https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2206596 Jan 05, 2024 - In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211770 Jan 17, 2024 - In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085 Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113 Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More https://www.zacks.com/stock/news/2222125/late-session-earnings-bonanza-ford-chipotle-snap-more?cid=CS-ZC-FT-ahead_of_wall_street-2222125 Feb 06, 2024 - Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates https://www.zacks.com/stock/news/2222190/gilead-gild-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2222190 Feb 06, 2024 - The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Pages: 12

Page 1